WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Enid Qin
Associate
Corporate
New York
yqin@wsgr.com

D212-453-2801

Download vCard
Open PDF

Enid (Yihan) Qin is an associate in the New York office of Wilson Sonsini Goodrich & Rosati, where she focuses on representation of public and private technology companies at all stages of growth. She practices corporate and securities law, including general corporate representation, venture capital, capital markets, and mergers and acquisitions matters.

Prior to joining the firm, Enid was an associate in the capital markets group of Kirkland & Ellis LLP in New York, where she represented issuers, private equity sponsors, and underwriters on capital-raising through public and private equity and debt offerings. Her experience includes high-yield debt offerings, initial public offerings, SPACs, de-SPAC transactions, preferred equity offerings, investment grade debt offerings, and tender and exchange offers. Enid also advised U.S. and international companies with respect to corporate and securities law matters, including corporate governance and SEC, NYSE, and Nasdaq disclosure, reporting, and compliance obligations.

Experience

Enid (Yihan) Qin is an associate in the New York office of Wilson Sonsini Goodrich & Rosati, where she focuses on representation of public and private technology companies at all stages of growth. She practices corporate and securities law, including general corporate representation, venture capital, capital markets, and mergers and acquisitions matters.

Prior to joining the firm, Enid was an associate in the capital markets group of Kirkland & Ellis LLP in New York, where she represented issuers, private equity sponsors, and underwriters on capital-raising through public and private equity and debt offerings. Her experience includes high-yield debt offerings, initial public offerings, SPACs, de-SPAC transactions, preferred equity offerings, investment grade debt offerings, and tender and exchange offers. Enid also advised U.S. and international companies with respect to corporate and securities law matters, including corporate governance and SEC, NYSE, and Nasdaq disclosure, reporting, and compliance obligations.

Education
  • J.D., New York University School of Law, 2019

    Staff Editor, Journal of Intellectual Property & Entertainment Law; Professional Chair, Asia Law Society

  • M.A., Strategic Public Relations, University of Southern California, 2014
  • B.A., Journalism, Peking University, 2012
Admissions
  • State Bar of New York
Credentials
Education
  • J.D., New York University School of Law, 2019

    Staff Editor, Journal of Intellectual Property & Entertainment Law; Professional Chair, Asia Law Society

  • M.A., Strategic Public Relations, University of Southern California, 2014
  • B.A., Journalism, Peking University, 2012
Admissions
  • State Bar of New York
Focus Areas
  • Capital Markets
  • Corporate
  • Emerging Companies and Venture Capital
Recent Insights
Client Highlights
Wilson Sonsini Advises Crosspoint Capital Partners on TENEX.AI’s $250 Million Series B
On March 31, 2026, TENEX.AI, the AI SOC company transforming security operations, announced a $250 million Series B round of financing led by Crosspoint Capital Partners. Wilson Sonsini Goodrich & Rosati advised Crosspoint on the transaction.

The proceeds from the Series B will accelerate TENEX.AI’s global expansion and significantly scale the human expertise behind its AI-native managed detection and response (MDR) service, expanding the team of defenders and engineers delivering cybersecurity outcomes. The TENEX.AI platform enables AI-driven triage, investigation, hunting, and response to threats in under a minute—with 100 percent alert coverage and human analysts governing every decision and accountable for every outcome.

The Wilson Sonsini team that advised Crosspoint on the financing included:

Corporate
Becki DeGraw
Travis Scheft
Michael Murrietta
Enid Qin
Learn More
Client Highlights
Wilson Sonsini Advises ALX Oncology on Public Offering
On January 30, 2026, ALX Oncology Holdings Inc., a clinical-stage biotechnology company focusing on novel therapies designed to treat cancer and extend patients’ lives, announced the pricing of an underwritten offering of 76,979,112 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,574,120 shares of common stock in the offering. The gross proceeds of the offering are expected to be approximately $150 million before deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any pre-funded warrants. Wilson Sonsini Goodrich & Rosati advised ALX Oncology on the transaction.
Learn More
View All
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.